Claims could not easily be made that beta-blockers as a group are the most potent or best-tolerated antihypertensive drugs. However, they have a very important role in the management of hypertensive patients who are being treated to prevent cardiovascular complications. Whilst stroke incidence can be reduced by effective blood pressure control, preventing the progress of coronary artery disease to reduce the patients risk of having a myocardial infarct, dying suddenly or developing heart failure is more difficult. Beta-blockers, particularly
Introduction
Doctor's opinions of the role of beta-blockers in the management of hypertension will be largely determined by their views of four subjects. First, what are their key aims when treating a hypertensive patient. For some, the prime objective is to achieve the maximum reduction in blood pressure (BP) with the minimum number of adverse effects. The alternative view is that the reason for treating high BP is to prevent cardiovascular complications, and particularly in the younger patients, that means myocardial infarction (MI) and sudden death. BP reduction does reduce the risk of having a stroke but has a modest impact on coronary risk.
1-3 Second, there is the link between hypertensive and coronary disease. Most doctors who treat hypertension fully understand that coronary risk increases as BP rises. 3 However, they treat their hypertensive patients, who have not yet had a recognisable myocardial infarct, as if they do not have coronary disease. It would seem that they imagine that the coronary arteries are clear one day and the next the patient has an infarct, perhaps associated with extensive coronary artery disease for which post infarct therapy is appropriate. The alternative view would be that most hypertensive patients are developing coronary artery disease which will one day become overt as a typical heart attack or possibly sudden death. Those who hold this view believe that coronary preventive measures such as lipid lowering, 4 aspirin therapy 5 and the choice of an antihypertensive drug with the potential to reduce coronary mortality and sudden death 6 would seem sensible, particularly when treating the middle-aged male hypertensive patient. Third, some believe that all beta-blockers are the same, others
Correspondence: MJ Kendall lipophylic beta-blockers, are the antihypertensive drugs for which there is most evidence that they reduce coronary mortality. Furthermore, the adverse effects of betablockers have been exaggerated and there is good evidence that the elderly, diabetics, and those with impaired left ventricular function do derive considerable benefit from beta-blockade. Low plasma concentrations of beta 1 selective drugs are clinically effective and are well tolerated.
believe that some of the pharmacological differences between different beta-blockers are important. Finally, some regard beta-blockers as drugs which are relatively toxic, badly tolerated and contraindicated in many groups of patients. Others, whilst accepting that some patients do not like being on a beta-blocker believe that low concentrations of beta selective beta 1 -blockers are relatively well tolerated and that the list of contraindications needs to be reduced. Diabetic, 7 elderly 8 and heart failure patients 9 may derive benefit from beta blockade.
Why am I treating this patient's blood pressure?
Those who treat hypertension need to answer this question when they plan the management of each patient. The ideal treatment should reduce BP, be well tolerated, safe, easy to take (ie, once daily by mouth) and not too expensive. It should also prevent complications. Stroke risk is reduced by effective BP control, 1 coronary risk is more difficult to reduce. However, since many patients would put survival as their priority, attempts to reduce the risk of an MI or sudden death should become a priority for the doctor. Effective BP reduction may not be enough.
The recently reported HOT Study 5 was performed to determine whether reductions in diastolic BP to below 90 mm Hg would be beneficial and safe. Though it would be possible to find some support for the belief that those who were treated with the aim of achieving a diastolic pressure of 80 mm Hg did better than those treated with the aim of reducing the diastolic pressure below 90 mm Hg, inspection of the data for deaths per 1000 patient years of treatment does not suggest that the more the pressure is reduced the greater the clinical benefit (see Figure 1 ). 
Primary and secondary prevention
There are a limited number of primary prevention studies, most can be criticised and many recent studies have been performed on very selective elderly populations.
10-13 These demonstrate convincingly that BP reduction effectively reduces the incidence of cerebrovascular events: an extremely valuable result. The impact on coronary events, however, is much less clear. Metoprolol reduced coronary events, 14 and sudden deaths 15 much more effectively than diuretics in the MAPHY Study and propranolol had some impact in the MRC study 16 when silent MIs were included. 17 However, atenolol was not very effective in the Cooper and Warrender Study, 18 the HAPPHY study 19, 20 or the MRC elderly study. 10 These different results will be discussed below. Data on primary prevention for other antihypertensive drugs is either lacking (alpha-blocker, ACE inhibitors) or limited (calcium channel blockers). 13 Data on diuretics is interesting. Early trials such as the VA studies 21 and the Australian trial 22 failed to demonstrate a convincing impact on coronary events.
1 Taken together the early trials, most of which had diuretics as their main antihypertensive agent, showed only a modest impact on coronary disease as compared to strokes.
1 Interestingly, the MRC elderly trial 10 and the SHEP study 12 did show that diuretics reduced coronary events. In the former 10 there were no data on sudden deaths, in the latter 12 chlorthalidone did not reduce sudden deaths.
In view of the inadequacy of the information from primary prevention trials, is it reasonable to obtain information from post infarct trials? Certainly not to assess the efficiency of drugs in terms of BP control, but perhaps, with some caution, to answer the question: does a particular drug have the potential to reduce the risk of a serious coronary event? A reinfarction may not be the same as the first infarction but it may be the best model we have.
The results of the major beta-blocker post MI trials assessing the impact of timolol, 23 metoprolol, 24, 25 and propranolol 26 are well known and these and other trials have been the subject of reviews. 27, 28 The reduction in sudden death is perhaps not fully appreciated. 6 This is important as about 50% of those who died in the early years after an infarct die suddenly 25, [29] [30] [31] and of those who present with coronary artery disease (ie, those with hypertension) about 20% present with sudden death. 6, 32 Interestingly concomitant beta-blocker therapy reduced mortality rates in the CAST, 33 EMIAT 34 and CAM-IAT 35 trials, in post MI patients with a history of arrhythmia or impaired left ventricular function. In these trials, anti-arrhythmic therapy or amiodarone alone failed to produce significant reductions in mortality.
In conclusion, overall the evidence that betablockers can reduce coronary events and sudden death is very strong, though most of the data are from post infarct studies. Primary prevention studies 14, 16 do show a positive impact for two lipophilic beta-blockers, metoprolol and propranolol, and the data for hypertensive patients are currently as persuasive as those are for any other antihypertensive drug.
Pharmacological differences between beta-blockers
Beta-blockers have a number of different pharmacological characteristics. Partial agonism and membrane stabilising activity are no longer regarded as clinically important. Beta 1 selectivity, on the other hand, is accepted as a way of reducing beta 2 -mediated adverse effects. 36 Much more important, though much less well recognised, is the fact that some beta-blockers which have been shown to reduce coronary events and sudden death in primary prevention or post infarct studies have been lipophilic. By comparison, those which have failed to produce an impact have been hydrophilic (see Table 1 ). The reason for this has been discussed. 6, 36, 37 
Contraindications to beta-blockade
It is often suggested that the list of contraindications to beta-blockade includes a large proportion of all those who might need an antihypertensive drug. Asthma at any time in the patients life is an undoubted absolute contraindication. The other absolute contraindication is heart failure. However beta-blockers are now being used to treat end stage heart failure [39] [40] [41] albeit with extreme care and under close observation. It is also relevant that in the BHAT study 26 in which propranolol, and the Swedish study in which metoprolol 24, 25 was given to post MI patients, those with evidence of ventricular dysfunction derived more benefit than those with more normal ventricular function. 42 The elderly have also been considered to be unlikely to tolerate betablockers. However, in the MRC elderly 10 and the STOP trial 11 there was no suggestion that the elderly were particularly vulnerable. Furthermore, a recently reported study of elderly post MI patients, though not a randomised trial, showed that those on a beta-blocker, even those over 85 years old, did better than those not on a beta-blocker. 8 Similarly, diabetic patients in post MI studies derive more benefit that the non-diabetic in that their life expectancy is improved. 7, 43 Finally, the limited objective evidence available does not suggest that beta-blockers are particularly dangerous in those with intermittent claudication. 44 There is no doubt that some patients do not tolerate beta-blockers well. Tolerability may be improved by using low doses of beta 1 selective drugs. However, standard preparations produce fluctuating plasma concentrations and at high concentration some beta 2 blockade occurs. 37, 45 Preparations such as metoprolol CR/ZOK (unfortunately not available in the UK) produce more even, low plasma concentration 
Conclusions
Those who prefer not to prescribe beta-blockers tend to believe that:
(1) The aim in treating hypertension is good BP control with few adverse effects. Quality of life is important. (2) Hypertension and coronary artery disease (CAD) are two distinct but related disorders and one should try to prevent the first infarct or sudden death by BP reduction. (3) All beta-blockers are the same. (4) Beta-blockers cause many adverse effects and are contraindicated in most patients.
Those who believe that beta-blockers still have a key role in the treatment of hypertension believe that:
(1) The aim in treating hypertension is to prevent cardiovascular complications and that whereas stroke incidence is reduced by BP control, reducing coronary risk requires additional measures. The choice of an antihypertensive drug with proven 'coronary preventive' properties seems sensible. (2) Hypertensive patients are not only at risk of having a coronary event, which may be fatal, but they are developing CAD more rapidly than normotensive individuals. Therefore measures known to reduce mortality in those known to have CAD (because they had an infarct) may have an important role on primary prevention. (3) All beta-blockers are not the same, most of those beta-blockers for which there is evidence of reduced coronary events in the long term are lipophilic beta-blockers. (4) Beta-blockers are contraindicated in asthmatics and should be used with extreme caution in those with heart failure. However, those with mild cardiac dysfunction, the elderly and diabetics all show greater mortality reductions that those either with more normal hearts or younger patients. 
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